Literature DB >> 16055815

Integrated treatment of first-episode psychosis: effect of treatment on family burden: OPUS trial.

Pia Jeppesen1, Lone Petersen, Anne Thorup, Maj-Britt Abel, Johan Oehlenschlaeger, Torben Ø Christensen, Gertrud Krarup, Ralf Hemmingsen, Per Jørgensen, Merete Nordentoft.   

Abstract

BACKGROUND: The families of patients with first-episode psychosis often play a major role in care and often experience lack of support. AIMS: To determine the effect of integrated treatment v. standard treatment on subjective burden of illness, expressed emotion (EE), knowledge of illness and satisfaction with treatment in key relatives of patients with a first episode of schizophrenia-spectrum disorder.
METHOD: Patients with ICD-10 schizophrenia-spectrum disorders (first episode) were randomly assigned to integrated treatment or to standard treatment. Integrated treatment consisted of assertive community treatment, psychoeducational multi-family groups and social skills training. Key relatives were assessed with the Social Behaviour Assessment Schedule (SBAS, burden of illness), the 5-min speech sample (EE), and a multiple choice questionnaire at entry and after 1 year.
RESULTS: Relatives in integrated treatment felt less burdened and were significantly more satisfied with treatment than relatives in standard treatment. There were no significant effects of intervention groups on knowledge of illness and EE.
CONCLUSIONS: The integrated treatment reduced family burden of illness and improved satisfaction with treatment.

Entities:  

Mesh:

Year:  2005        PMID: 16055815     DOI: 10.1192/bjp.187.48.s85

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  34 in total

Review 1.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Model fidelity of assertive community treatment for clients with first-episode psychosis: a target group-specific application.

Authors:  M J M Verhaegh; I M B Bongers; H Kroon; H F L Garretsen
Journal:  Community Ment Health J       Date:  2008-10-16

Review 3.  Relapse risk assessment in early phase psychosis: the search for a reliable and valid tool.

Authors:  Phil Tibbo; Ashok Malla; Rahul Manchanda; Richard Williams; Ridha Joober
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

4.  A randomized controlled trial of bibliotherapy for carers of young people with first-episode psychosis.

Authors:  Terence V McCann; Dan I Lubman; Sue M Cotton; Brendan Murphy; Kingsley Crisp; Lisa Catania; Claudia Marck; John F M Gleeson
Journal:  Schizophr Bull       Date:  2012-11-20       Impact factor: 9.306

5.  The feasibility of cognitive adaptation training for outpatients with schizophrenia in integrated treatment.

Authors:  Jens Peter Hansen; Birte Østergaard; Merete Nordentoft; Lise Hounsgaard
Journal:  Community Ment Health J       Date:  2012-10-12

Review 6.  Early intervention for psychosis.

Authors:  Max Marshall; John Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 7.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 8.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Hanna Bergman; Mariam A Khokhar; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2017-01-06

9.  At issue: Cochrane, early intervention, and mental health reform: analysis, paralysis, or evidence-informed progress?

Authors:  Patrick McGorry
Journal:  Schizophr Bull       Date:  2012-01-12       Impact factor: 9.306

10.  Stigma in families of individuals in early stages of psychotic illness: family stigma and early psychosis.

Authors:  Celine Wong; Larry Davidson; Deirdre Anglin; Bruce Link; Ruth Gerson; Dolores Malaspina; Thomas McGlashan; Cheryl Corcoran
Journal:  Early Interv Psychiatry       Date:  2009-05       Impact factor: 2.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.